24-169 Phase I
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
Search Cancer Clinical Trials
Mass General Brigham Cancer Institute offers patients access to a wide variety of
clinical trials of promising new therapies. Use the search tool to find open protocols
for your type of cancer.
10 results
21-385 Phase I
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
25-287 Phase I
A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors
20-544 Phase II
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
23-340 Phase II
A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors
25-448 Phase II
A Phase 1/2 Study of GEN1286 in Patients with Advanced Solid Tumors
24-486 Phase III
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
24-242 Phase II
A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab with Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors
23-618 Phase I
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
22-499 Phase I
An Open-label, Multicenter, Phase 1, First in Human, Dose Escalation and Expansion Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
Showing 1 - 10 of 10 results